Optiver Holding’s Pacific Biosciences PACB Stock Holding History

Optiver Holding’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41K	Sell	1,436 -704	-33%	-$1.02K	﹤0.01%	2255
2026 Q1	$2.83K	Buy	+2,140	New	+$3.83K	﹤0.01%	1697
2025 Q3	–	Sell	-60,178	Closed	-$74.6K	–	2833
2025 Q2	$74.6K	Buy	60,178 +10,840	+22%	+$12.5K	﹤0.01%	569
2025 Q1	$58.2K	Buy	49,338 +48,598	+6,567%	+$74.5K	﹤0.01%	500
2024 Q4	$1.35K	Buy	+740	New	+$1.44K	﹤0.01%	967
2024 Q3	–	Sell	-3,491	Closed	-$4.78K	–	1058
2024 Q2	$4.78K	Buy	+3,491	New	+$7.05K	﹤0.01%	800

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Optiver Holding's PACB Position: Q2 2026 in Review

Optiver Holding reduced its Pacific Biosciences (PACB) stake by 33% in Q2 2026, selling an estimated $1.02K and leaving 1,436 shares worth $2.41K. The position accounts for ﹤0.01% of the portfolio, ranked #2255.

Optiver Holding first reported a position in PACB in Q2 2024 and has held it in 6 quarters since. The position peaked at $74.6K in Q2 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Optiver Holding held 1,436 shares of Pacific Biosciences worth $2.41K as of Q2 2026.
Optiver Holding sold 704 Pacific Biosciences shares in Q2 2026, an estimated $1.02K.
Pacific Biosciences made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2255 holding.
Optiver Holding first reported a position in Pacific Biosciences in Q2 2024 and has held it in 6 quarters since.
Optiver Holding's Pacific Biosciences position peaked at $74.6K in Q2 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.